Loyal and stubborn heroes: the main character’s personality in Classic Hollywood cinema

This research aims to analyze the main characters’ construction in classic Hollywood cinema by focusing on their personalities. This work follows Bordwell, Staiger and Thompson’s notions of classic cinema. The sample includes films from 1930 to 1960. Character is understood as personality and as a psychological unit. Characterization is defined by each trait that refers to the totality of their character. We start with the hypothesis that there are central tendencies for creating heroes and heroines in classic cinema. However, these tendencies also correspond with the film narrative model, which is shaped by the functionality of the narrative categories in the story. Personality is among those factors that shape the construction of the character. We applied a methodology of film narrative analysis to a sample of 64 films from six extensive genres in classic Hollywood cinema. The results confirm that the main character in classic cinema is conditioned and shaped by their adaptation to the film’s genre. The hero is usually positive according to what is considered socially acceptable values; the dramatic needs of the plot predetermine their definition. The Hollywood main character’s personality is based on their functionality as they serve the narrative needs of the story

Relativistic particle dynamics in D=2+1

We propose a SUSY variant of the action for a massless spinning particles via the inclusion of twistor variables. The action is constructed to be invariant under SUSY transformations and $\tau$-reparametrizations even when an interaction field is including. The constraint analysis is achieved and the equations of motion are derived. The commutation relations obtained for the commuting spinor variables $\lambda$ show that the particle states have fractional statistics and spin. At once we introduce a possible massive term for the non-interacting model.Comment: 11 page

Metástasis Vertebrales

La incidencia de las metástasis en columna vertebral está aumentando por el incremento de la población anciana, la mayor esperanza de vida y las mejores en el tratamiento de los pacientes con cáncer. Revi - samos el diagnóstico y tratamiento de estos pacientes.The incidence of spinal metastases is increasing with increasingly older populations, longer life expectancy and improvements in medical treatment of the patients with cancer. So, metastases to the spine repre - sent a challenging problem. We review diagnosis and treatment these patients

A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects

BACKGROUND AND AIMS: Metformin, the most prescribed drug for the treatment of type 2 diabetes mellitus, has been recently reported to promote weight loss by upregulating the anorectic cytokine growth differentiation factor 15 (GDF15). Since the antidiabetic effects of metformin are mostly mediated by the activation of AMPK, a key metabolic sensor in energy homeostasis, we examined whether the activation of this kinase by metformin was dependent on GDF15. METHODS: Cultured hepatocytes and myotubes, and wild-type and Gdf15(-/-) mice were utilized in a series of studies to investigate the involvement of GDF15 in the activation of AMPK by metformin. RESULTS: A low dose of metformin increased GDF15 levels without significantly reducing body weight or food intake, but it ameliorated glucose intolerance and activated AMPK in the liver and skeletal muscle of wild-type mice but not Gdf15(-/-) mice fed a high-fat diet. Cultured hepatocytes and myotubes treated with metformin showed AMPK-mediated increases in GDF15 levels independently of its central receptor GFRAL, while Gdf15 knockdown blunted the effect of metformin on AMPK activation, suggesting that AMPK is required for the metformin-mediated increase in GDF15, which in turn is needed to sustain the full activation of this kinase independently of the CNS. CONCLUSION: Overall, these findings uncover a novel mechanism through which GDF15 upregulation by metformin is involved in achieving and sustaining full AMPK activation by this drug independently of the CNS

In vitro plant regeneration system for common bean ( Phaseolus vulgaris ): effect of N6-benzylaminopurine and adenine sulphate

A method for regeneration of the commercially important common bean ( Phaseolus vulgaris ) using N6-benzylaminopurine(BAP) and adenine sulphate (AS) was established. Embryogenic axes of the Costa Rican common bean cultivars Bribr\ued, Brunca, Guaym\ued, Huetar and Telire were cultured on Murashige and Skoog medium supplemented with 100 mgl-1 myo-inositol, 1 mgl-1 thiamine, 30 gl-1 sucrose, BAP (0, 5 and 10 mgl-1), AS (0, 20 and 40 mgl-1) and 8 gl-1 agar. Regardless of the concentration of BAP and AS in the induction medium, the number of shoots and leaves differed significantly among the common bean cultivars evaluated. The higher average of shoots was obtained for Brunca > Telire > Bribr\ued > Guaym\ued > Huetar. Moreover, independently of the cultivar, the induction medium supplemented with 5 mgl-1 BAP and 20 or 40 mgl-1 AS resulted in the higher average of shoots formation. Culture of Bribr\ued, Brunca, Guaym\ued, Huetar and Telire embryogenic axes on induction medium supplemented with different BAP and AS resulted in a differential response. Successful acclimatization of common bean in vitro plants were achieved in the greenhouse, and plants appeared morphologically normal. The regeneration system developed in this investigation for this important crop could be a useful tool for the genetic modification through mutagenesis or genetic transformation

Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): Study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III)

Background: Perinatal asphyxia and resulting hypoxic-ischemic encephalopathy is a major cause of death and long-term disability in term born neonates. Up to 20,000 infants each year are affected by HIE in Europe and even more in regions with lower level of perinatal care. The only established therapy to improve outcome in these infants is therapeutic hypothermia. Allopurinol is a xanthine oxidase inhibitor that reduces the production of oxygen radicals as superoxide, which contributes to secondary energy failure and apoptosis in neurons and glial cells after reperfusion of hypoxic brain tissue and may further improve outcome if administered in addition to therapeutic hypothermia. Methods: This study on the effects of ALlopurinol in addition to hypothermia treatment for hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO), is a European double-blinded randomized placebo-controlled parallel group multicenter trial (Phase III) to evaluate the effect of postnatal allopurinol administered in addition to standard of care (including therapeutic hypothermia if indicated) on the incidence of death and severe neurodevelopmental impairment at 24 months of age in newborns with perinatal hypoxic-ischemic insult and signs of potentially evolving encephalopathy. Allopurinol or placebo will be given in addition to therapeutic hypothermia (where indicated) to infants with a gestational age 65 36 weeks and a birth weight 65 2500 g, with severe perinatal asphyxia and potentially evolving encephalopathy. The primary endpoint of this study will be death or severe neurodevelopmental impairment versus survival without severe neurodevelopmental impairment at the age of two years. Effects on brain injury by magnetic resonance imaging and cerebral ultrasound, electric brain activity, concentrations of peroxidation products and S100B, will also be studied along with effects on heart function and pharmacokinetics of allopurinol after iv-infusion. Discussion: This trial will provide data to assess the efficacy and safety of early postnatal allopurinol in term infants with evolving hypoxic-ischemic encephalopathy. If proven efficacious and safe, allopurinol could become part of a neuroprotective pharmacological treatment strategy in addition to therapeutic hypothermia in children with perinatal asphyxia. Trial registration: NCT03162653, www.ClinicalTrials.gov, May 22, 2017